arrowhead läuft - zu recht
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
http://ir.arrowheadpharma.com/releasedetail.cfm?ReleaseID=1057707
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
http://ir.arrowheadpharma.com/releasedetail.cfm?ReleaseID=1058336
3:10 PM UK
SMI RNA Therapeutics Conference
Location: London
http://files.shareholder.com/downloads/...rowhead_Pharmaceuticals.pdf
AsiaTIDES: Oligonucleotide and Peptide Therapeutics
Arrowhead’s TRiM™ Delivery System – Potent, Modular, and Versatile for RNAi Bruce D. Given,
http://ir.arrowheadpharma.com/static-files/...-4cc3-86ee-142fc21906c1
Recent Advances in RNAi Therapeutics at Arrowhead Pharmaceuticals Zhen Li, Ph.D., SVP Chemistry and Manufacturing
Location:
Kyoto, Japan
http://ir.arrowheadpharma.com/static-files/...-44ba-b9bf-b40175cc5017
https://drive.google.com/file/d/1Q14L9dBLn3hR8hzcUmgzW4ce2I39py4x/view
Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
https://www.businesswire.com/news/home/20180312005310/en/
Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
March 27, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/...sing-Phase-12-Study-ARO-HBV
Jefferies initiates coverage on Arrowhead Research (NASDAQ: ARWR) with a Buy rating and a price target of $10.00.Analyst Maury Raycroft .
https://www.streetinsider.com/Analyst+Comments/...t+Buy/13986265.html
Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
March 28, 2018 07:30 AM Eastern Daylight Time
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical and pre-clinical data on the company’s investigational medicines for the treatment of chronic hepatitis B infection (ARC-520 and ARO-HBV) and liver disease associated with alpha-1 antitrypsin deficiency (ARO-AAT), at The International Liver Congress™ 2018, the annual meeting of the European Association for the Study of the Liver (EASL), being held in Paris from April 11-15, 2018.
https://www.businesswire.com/news/home/...-Liver#.WruBGQGrnSo.twitter
Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™
April 11, 2018 07:00 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180411005375/en/
Key results include the following:
One HBeAg-negative patient serocleared HBsAg post ARC-520
Mild ALT changes off ARC-520 therapy coincided with sustained host responses in 2/3 HBeAg- positive and 2/5 HBeAg-negative patients
A single dose of ARC-520 in combination with ETV reduced HBsAg for up to 44 weeks
Multiple doses of ARC-520 resulted in additional HBsAg reductions in all patients by as much 5.3 Log10
ARC-520 in combination with ETV was effective at rapidly suppressing HBV DNA
World Orphan Drug Congress USA 2018
http://ir.arrowheadpharma.com/static-files/...-4c68-8bd2-9918dfc44cdd
https://www.businesswire.com/news/home/20180501005558/en/
American Thoracic Society (ATS) 2018 International Conference – San Diego, May 18-23, 2018
May 21, 9:15 a.m.-4:15 p.m. PDT – Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver a poster presentation titled, “Targeting αENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis.” In this presentation, Dr. Bush will present new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, targeting the epithelial sodium channel alpha subunit (αENaC) for the treatment of cystic fibrosis.
https://seekingalpha.com/article/...cal-q2-2018-results-earnings-call
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Arrowhead Pharmaceutica |
https://www.pharmaceutical-journal.com/...of-success/20204853.article
Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis
May 21, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180521005437/en/
Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences
May 30, 2018 07:25 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180530005534/en/
Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV
May 30, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180530005538/en/
Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
June 18, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180618005327/en/
Two planned cohorts at a dose of 400 mg were eliminated because maximal activity appeared to occur at lower doses than expected.
Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
June 27, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180627005432/en/
Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference
June 29, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/20180629005141/en/
August 01, 2018 07:30 AM Eastern Daylight Time
https://www.businesswire.com/news/home/...0-Million-Milestone-Payment
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study designed to assess its safety in volunteers with elevated levels of lipoprotein (a) (Lp(a)). Emerging research has shown that elevated levels of Lp(a) are strongly associated with cardiovascular disease. AMG 890 is an RNAi therapeutic designed to lower Lp(a) for the treatment of cardiovascular disease.
https://madison-com.cdn.ampproject.org/v/s/...-b8ac-9a3f9f42ba26.html
Auszug
Arrowhead plans to seek federal regulatory approval to start clinical trials on three more products before the end of the year. Two are cardiometabolic — referring to cardiovascular disease and diabetes — and one targets cystic fibrosis, said Vincent Anzalone, vice president of finance and investor relations. A prospective drug against kidney cancer is on the agenda for 2019 and there is “a handful of others beyond that,” he said, all built on the targeted RNAi molecule platform.